Further to your request for information dated 28 September 2015 the information requested is below/attached:

1. Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:

   (a) What was the prevalence of atrial fibrillation (AF)?

   NHS Dartford Gravesham and Swanley Clinical Commissioning Group does not hold this information.

   (b) How many patients were diagnosed with AF

   3,968

   (c) How many patients received a manual pulse check for AF

   NHS Dartford Gravesham and Swanley Clinical Commissioning Group (CCG) does not hold this data.

2. Which of the criteria listed below is included in the personalised package of care offered to patients with AF?

Please refer to the pathway attached. Also, please contact provider Darent Valley Hospital DVH AF Service Darent Wood Road Dartford Kent DA2 8DA or individual GP practices for details of personalised care package.

3. What steps does your CCG take to verify that patients with AF are being offered a personalised package of care?

The CCG does not currently monitor this.
4. **What support networks and information are advertised and provided to patients with AF.**

For the reply to this question, please contact the provider at

Darent Valley Hospital DVH AF Service Darenth Wood Road Dartford Kent DA2 8DA or individual GP practices for details of personalised care package.

5. **Between 1 July 2014 and 20 June 2015, how many patients in the area covered by your CCG have been referred to specialised management due to**

   (a) **Failure of AF treatment to control the symptoms of AF?**

   The CCG does not have this data. This data may be held by the South East Coast Cardiovascular Strategic Clinical Network


   (b) **Recurrence of AF following cardioversion**

   The CCG does not have this data. The data may be held by the South East Coast Cardiovascular Strategic Clinical Network


6. **What steps do your providers take to ensure that people with any of the above conditions are assessed for AF-related stroke risk using the CHA2DS2-VASc stroke risk score.**
7. What steps do your providers take to ensure that the HAS-BLED score is used to assess the risk of bleeding in people who are starting or have started anticoagulation.

Please refer to the attached pathway.

8. Of the patients who were treated for AF in the area covered by your CCG between 1 July 2014 and 30 June 2015, how many had a CHA2DS2-VASc score of 2 or above.

The CCG does not hold this data.

9. Of these patients, how many were treated for AF-related stroke prevention with:

(a) Anticoagulation therapy (therapy which reduces the body’s ability to form clots in the blood)?.

The CCG does not hold this information

(b) Aspirin monotherapy (the treatment of AF with aspirin alone)?

The CCG does not hold this data.

10. What guidance do you give to your providers to ensure they are prescribing an appropriate anticoagulant approved by NICE for AF-related stroke prevention rather than aspirin monotherapy?

Please see attached pathway.
11. Of the patients treated with anticoagulation therapy for AF-related stroke prevention in the area covered by your CCG between 1 July 2014 and 30 June 2015, what percentage were treated with:

(a) A Novel oral anticoagulant (NOAC)

(b) Warfarin

12. Do your providers offer rate-control as the first-line strategy to patients with AF?

Yes they do. Please refer to attached pathway.